


## LEGENDS TO SUPPLEMENTARY FIGURES

**Supplementary Figure 1.** Interaction of FxxLF, FxxFF, and LxxLL peptides with AR L701 mutants in the presence of anti-androgens. Interaction of the AR FxxLF motif (KTYRGAFQNLFQSVRE; Dubbink et al., 2004), and FxxFF (SRFADFFRNEGLSGSR; Hur et al., 2004), and LxxLL (SSRGLLWDLTKDSR; Hur et al., 2004) motifs with wild type AR (A), AR L701M (B), AR L701H (C), AR L701Q (D), AR T877A (E), and AR L701H/T877A (F) were determined in the presence of DHT (100 nM) and the anti-androgens hydroxyflutamide (OHF; 1  $\mu$ M) and cyproterone acetate (CPA; 1  $\mu$ M). Assays were performed as described in the legend to Figure 6. The results of a representative assay performed in duplicate (+/- SD) are shown.






**Supplementary Figure 2.** Interaction of LxxLL and FxxLF-like peptides with AR L701 mutants. (A to D) Interaction of the AR FxxLF (KTYRGAFQNLFQSVRE; Dubbink et al., 2004), Gelsolin FxxFF (GGETPLFKQFFKNWRD; van de Wijngaart et al., 2006), and PAK6 FxxMF (SLKRRLFRSMFLSTAA; van de Wijngaart et al., 2006) motifs with wild type AR (A), AR L701M (B), AR L701H (C), and AR L701Q (D) were determined in the presence of DHT (100 nM), progesterone (1  $\mu$ M), and cortisol (1  $\mu$ M). Assays were performed as described in the legend to Figure 6. The results of a representative assay performed in duplicate (+/- SD) are shown. (E) Interaction of the AR FxxLF (Dubbink et al., 2004), Gelsolin FxxFF (van de Wijngaart et al., 2006), SRC1 box1 LxxLL and FxxLF (SQTSHKL/FVQLL/FTTTAE; Dubbink et al., 2006), and D11 LxxLL (ESGSSRLMQLLMANDL; Dubbink et al., 2006) motifs with wild type AR, AR L701I, and AR L701F were determined in the presence of increasing DHT concentrations (1 nM, 10 nM, and 100 nM). Assays were performed as described in the legend to Figure 6. The results of a representative assay performed in duplicate (+/- SD) are shown.

## References

- Dubbink, H. J., Hersmus, R., Verma, C. S., van der Korput, H. A., Berrevoets, C. A., van Tol, J., Ziel-van der Made, A. C., Brinkmann, A. O., Pike, A. C., and Trapman, J. (2004) *Mol Endocrinol* **18**(9), 2132-2150
- Dubbink, H. J., Hersmus, R., Pike, A. C., Molier, M., Brinkmann, A. O., Jenster, G., and Trapman, J. (2006) *Mol Endocrinol* **20**(8), 1742-1755
- Hur, E., Pfaff, S. J., Payne, E. S., Gron, H., Buehrer, B. M., and Fletterick, R. J. (2004) *PLoS Biol* **2**(9), E274
- van de Wijngaart, D. J., van Royen, M. E., Hersmus, R., Pike, A. C., Houtsmuller, A. B., Jenster, G., Trapman, J., and Dubbink, H. J. (2006) *J Biol Chem* **281**(28), 19407-19416



Supplementary Figure 1



Supplementary Figure 2